10-Q · May 13, 2026
Century Therapeutics (IPSC) reported significant revenue decline in Q1 2026 due to the cessation of collaboration revenue from its partnership with Bristol-Myers Squibb. The company continues to show negative net income…
Earnings analysis · 10-Q
IPSC earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not provide current-quarter income statement, segment, or cash-flow figures, so revenue, margins, EPS, and free cash flow cannot be quantified from the available filing text. Liquidity consisted…
Read full summary
The extracted 10-Q does not provide current-quarter income statement, segment, or cash-flow figures, so revenue, margins, EPS, and free cash flow cannot be quantified from the available filing text. Liquidity consisted of $52.0 million of cash, cash equivalents, and restricted cash and $147.5 million of investments as of June 30, 2026. Management identified banking disruption and interest-rate sensitivity risks, while reporting no material changes to the risk factors in the 2025 Form 10-K; no quantitative guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$199.5M cash and investments
The company reported $52.0 million of cash, cash equivalents, and restricted cash as of June 30, 2026, plus $147.5 million of investments, providing a liquidity base for ongoing operations.
-
Limited interest-rate exposure
Management stated that its low-risk investment portfolio means changes in market interest rates would not have a material impact on financial condition or results of operations; investments totaled $147.5 million at June 30, 2026.
-
Disclosure controls effective
Management concluded that disclosure controls were effective at a reasonable assurance level as of June 30, 2026.
What to watch
-
Banking access risk
Disruptions at financial institutions or in the financial-services industry could impair access to cash and cash equivalents. The company held $52.0 million of cash, cash equivalents, and restricted cash as of June 30, 2026.
-
Interest income sensitivity
Interest income is sensitive to U.S. interest-rate levels, with $147.5 million of investments exposed to changes in market rates, although management characterized the portfolio as low risk and the potential impact as not material.
-
No new risk-factor changes
The company stated that there were no material changes to the risk factors disclosed in its 2025 Form 10-K, so no new filing-specific risk-factor escalation was identified.
Management's outlook
No quantitative revenue or EPS guidance was provided in the extracted 10-Q. The filing does not include an explicit forward outlook.
Earlier filings 4
10-K · March 12, 2026
Century Therapeutics (IPSC) positions itself as an iPSC-derived, allogeneic cell therapy company centered on proprietary Allo‑Evasion™ engineering and in‑house scalable manufacturing. The company has moved its beta…
10-Q · May 9, 2024
Century Therapeutics reported collaboration revenue of $855,000 for the quarter and a net loss of $28,062,000 (net loss per share $0.45). Revenue declined from $1,720,000 in the prior-year quarter while EPS improved…
10-Q · November 9, 2023
Century Therapeutics (IPSC) reported Q3 collaboration revenue of $148,000 (vs. $2,224,000 in Q3 2022) and a GAAP net loss of $32,720,000 (EPS -$0.55), with operating expenses of $35,774,000. Liquidity remains sizable —…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.